Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 18/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | FPR3 | P25089 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | P2RY13 | Q9BPV8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074060 | 0.86 | P2RY12 (0.79) | P2RY12CYP2C9 | |
| SCHEMBL5099395 | 0.86 | P2RY12 (0.69) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL7000932 | 0.84 | P2RY12 (1.00) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| Acetic Acid SCHEMBL5109669 | 0.83 | P2RY12 (0.66) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL5729485 | 0.83 | P2RY12 (1.00) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL2066591 | 0.83 | P2RY12 (0.76) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL2065338 | 0.83 | P2RY12 (1.00) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL10074052 | 0.83 | P2RY12 (0.76) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL7482538 | 0.83 | P2RY12 (0.84) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL10074061 | 0.83 | P2RY12 (1.00) | P2RY12CYP2C9PGRADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335918-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | EP | claimed |
| US-6844348-B2 | 2,3,4-cyclopentan-2,3,4-triol-1-yl compounds | ASTRAZENECA AB (SE) | 2005-01-18 | — | — | US | claimed |
| US-20040029899-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | US | claimed |
| US-7345047-B2 | Substituted [1,2,3]triazolo[4,5-d]pyrimidines | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | disclosed |
| EP-1335918-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| US-20050143399-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | US | disclosed |
| US-6844348-B2 | 2,3,4-cyclopentan-2,3,4-triol-1-yl compounds | ASTRAZENECA AB (SE) | 2005-01-18 | — | — | US | disclosed |
| US-20040029899-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029899-A1 | Novel compounds | CNR2, PTGIS, CYP11B2 | P2RY12 127/4885CYP2C9 486/4885PGR 1714/4885 |
| US-20050143399-A1 | Novel compounds | CNR2, PTGIS, CYP11B2 | P2RY12 127/4885CYP2C9 486/4885PGR 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.